How were new medicines discovered? (original) (raw)

• Munos, B. Lessons for 60 years of pharmaceutical innovation. Nature Rev. Drug Discov. 8, 959–968 (2009).
  Article CAS Google Scholar
• Paul, S. M. et al. How to improve R.&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203–214 (2010).
  Article CAS Google Scholar
• Lindsay, M. A. Target discovery. Nature Rev. Drug Discov. 2, 831–838 (2003).
  Article CAS Google Scholar
• Imming, P., Sinning, C. Meyer A. Drugs, their targets and the nature and number of drug targets. Nature Rev. Drug Discov. 5, 821–834 (2006).
  Article CAS Google Scholar
• Overington, J. P., Al-Lazikani, B. & Hopkins, A. L. How many drug targets are there? Nature Rev. Drug Discov. 5, 993–996 (2006).
  Article CAS Google Scholar
• Williams, M. Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? Biochem. Pharmacol. 70, 1707–1716 (2005).
  Article CAS PubMed Google Scholar
• Flordellis, C. S., Manolis, A. S., Paris, H. & Karabinis, A. Rethinking target discovery in polygenic diseases. Curr. Top. Med. Chem. 6, 1791–1798 (2006).
  Article CAS PubMed Google Scholar
• Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 320, 1–13 (2007). Formalizes the concept of functional selectivity, whereby multiple unique ligands can bind to one receptor to initiate different responses.
  Article CAS PubMed Google Scholar
• Kenakin, T. & Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on drug discovery. Pharmacol. Rev. 62, 265–304 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Swinney, D. C. Biochemical mechanisms of drug action: what does it take for success? Nature Rev. Drug Discov. 3, 801–808 (2004). Describes how the MMOA influences the therapeutic index and utility of a medicine and introduces biochemical efficiency as a metric to quantify this influence.
  Article CAS Google Scholar
• Swinney, D. C. Biochemical mechanisms of new molecular entities (NMEs) approved by United States FDA during 2001–2004: mechanisms leading to optimal efficacy and safety. Curr. Top. Med. Chem. 6, 461–478 (2006).
  Article CAS PubMed Google Scholar
• Swinney, D. C. Applications of binding kinetics to drug discovery: translation of binding mechanism to clinically differentiated therapeutic responses. Pharm. Med. 22, 23–34 (2008).
  Article Google Scholar
• Yun, C.H. et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc. Natl Acad. Sci. USA 105, 2070–2075 (2008). Provides an illustration of how drug resistance could be overcome through an understanding of the MMOA.
  Article CAS PubMed PubMed Central Google Scholar
• Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753–758 (1997). Shows structurally how agonists and antagonists bind at the same site but with different binding modes that result in different responses.
  Article CAS PubMed Google Scholar
• Roth, G. J. & Majerus, P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56, 624–632 (1975).
  Article CAS PubMed PubMed Central Google Scholar
• Majerus, P. W., Broze, G. J. Jr, Miletich, J. P. & Tollefsen, D. M. in Goodman & Gilman's The pharmacological basis of therapeutics. (eds Hardman, J. G. & Limbird, L. E.) 1353 (McGraw-Hill, New York, 1996).
  Google Scholar
• Copeland, R. A., Pompliano, D. L. & Meek, T. D. Drug-target residence time and its implications for lead optimization. Nature Rev. Drug Discov. 5, 730–739 (2006).
  Article CAS Google Scholar
• Timmino, P. J. & Copeland, R. A. Residence time of receptor–ligand complexes and its effect on biological function. Biochemistry 47, 5481–5492 (2008).
  Article CAS Google Scholar
• Lu, H. & Tonge, P. J. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14, 1–8 (2010).
  Article CAS Google Scholar
• Johnson, D. S., Weerapana, E. & Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem. 2, 949–964 (2010).
  Article CAS PubMed Google Scholar
• Ohlson, S. Designing transient binding drugs: a new concept for drug discovery. Drug Discov. Today 13, 433–439 (2008).
  CAS Google Scholar
• Lipton, S. A. Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyond. Nature Rev. Drug Discov. 5, 160–170 (2006).
  Article CAS Google Scholar
• Lipton, S. A. Pathology activated therapeutics for neuroprotection. Nature Rev. Neurosci. 8, 803–808 (2007). Describes the principle that drugs should be activated by the pathological state that they are intended to inhibit.
  Article CAS Google Scholar
• Changeux, J. P. Allosteric receptors: from electric organ to cognition. Annu. Rev. Pharmacol. Toxicol. 50, 1–38 (2010).
  Article CAS PubMed Google Scholar
• Conn, J. P., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41–54 (2009).
  Article CAS Google Scholar
• Hanck, D. A. et al. Using lidocaine and benzocaine to link sodium channel molecular conformations to state-dependent antiarrhythic drug affinity. Circ. Res. 105, 492–499 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Butterworth, J. F. & Strichartz, G. R. Molecular mechanisms of local anesthesia: a review. Anesthesiology 72, 711–734 (1990).
  Article CAS PubMed Google Scholar
• Wilson, D. N. et al. The oxazolidinone antibiotics perturb the ribosomal peptidyl-transferase center and effect tRNA positioning. Proc. Natl Acad. Sci. USA 105, 13339–13344 (2008).
  Article PubMed PubMed Central Google Scholar
• Nemeth, E. F. Misconceptions about calcimimetics. Ann. NY Acad. Sci. 1068, 471–476 (2006). Discusses lessons learned in the discovery of cinacalcet, with emphasis on the importance of using an understanding of physiology.
  Article CAS PubMed Google Scholar
• Salisbury, B. G. et al. Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Athlerosclerosis 115, 45–63 (1995).
  Article CAS Google Scholar
• Valentino, D. et al. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl Acad. Sci. USA 90, 7894–7897 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461–477 (2007). Describes the successes of natural products as a source for new drugs.
  Article CAS PubMed Google Scholar
• Deacon, C. F. Therapeutic strategies based on glucagon-like peptide-1. Diabetes 53, 2181–2189 (2004).
  Article CAS PubMed Google Scholar
• Von Itzstein, M. et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363, 418–423 (1993).
  Article CAS PubMed Google Scholar
• Weibel, E. K., Hadvary, P., Hochuli, E., Kupfer, E. & Lengsfeld, H. Lipstatin, an inhibitor of pancreatic lipase produced by Streptomyces toxytricini. 1. Producing organism, fermentation, isolation and biological activity. J. Antibiot. 40, 1081–1086 (1987).
  Article CAS Google Scholar
• Kluter, D. J. New thrombopoietic growth factors. Blood 109, 4607–4616 (2007).
  Article CAS Google Scholar
• Remuzzi, G. et al. New therapeutics that antagonize endothelin: promises and frustrations. Nature Rev. Drug Discov. 1, 986–1001 (2002).
  Article CAS Google Scholar
• Wood, J. M. et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem. Biophys. Res. Commun. 308, 698–705 (2003).
  Article CAS PubMed Google Scholar
• Pommier, Y. et al. Integrase inhibitors to treat HIV/AIDS. Nature Rev. Drug Discov. 4, 236–248 (2005).
  Article CAS Google Scholar
• Espeseth, A. S. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl Acad. Sci. USA 97, 11244–11249 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lichtner, R. B. et al. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline kinase inhibitors. Cancer Res. 61, 5790–5795 (2001).
  CAS PubMed Google Scholar
• Barker, A. J. et al. Studies leading to the identification of ZD1830 (Iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911–1914 (2001).
  Article CAS PubMed Google Scholar
• Leader, B., Baca, Q. J. & Golan, D. E. Protein therapeutics: a summary and pharmacological classification. Nature Rev. Drug Discov. 7, 21–39 (2008).
  Article CAS Google Scholar
• Wilhelm, S. et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nature Rev. Drug Discov 5, 835–844 (2006).
  Article CAS Google Scholar
• Goke, R. et al. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting β-cells. J. Biol. Chem. 268, 19650–19655 (1993).
  CAS PubMed Google Scholar
• Alvaro, G. & Di Fabio, R. Neurokinin 1 receptor antagonists — current prospects.Curr. Opin. Drug Discov. Dev. 10, 613–621 (2007).
  CAS Google Scholar
• Wijayaratne, A. L. & McDonnell, D. P. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276, 35684–35692 (2001).
  Article CAS PubMed Google Scholar
• Ferrara, N. et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev. Drug Discov. 3, 391–400 (2004).
  Article CAS Google Scholar
• Capdeville, R., Buchdunger, E., Zimmermann, J. Matter A. Glivec (ST571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug. Discov. 1, 493–502 (2002).
  Article CAS Google Scholar
• Wacker, D. et al. Conserved binding mode of human β2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J. Am. Chem. Soc. 132, 11443–11445 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 141, 1117–1134 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Li, P. et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91, 479–489.
• Johnson, K. A. Role of induced fit in enzyme specificity: a molecular forward/reverse switch. J. Biol. Chem. 283, 26297–26301 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sigoillot, F. D. & King, R. W. Vigilance and validation: keys to success in RNAi screening. ACS Chem. Biol. 6, 47–60 (2011).
  Article CAS PubMed Google Scholar
• Hergenrother, P. J. & Palchaudhuri, R. Transcript profiling and RNA interference as tools to identify small molecule mechanisms and therapeutic potential. ACS Chem. Biol. 6, 21–33 (2011).
  Article CAS PubMed Google Scholar
• Macarron, R. et al. Impact of high-throughput screening in biomedical research. Nature Rev. Drug. Discov. 10, 188–195 (2011).
  Article CAS Google Scholar
• Pruss, R. M. Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms. CNS Neurol. Disord. Drug Targets 9, 693–700 (2010).
  Article CAS PubMed Google Scholar
• Bickle, M. The beautiful cell: high-content screening in drug discovery. Anal. Bioanal. Chem. 398, 219–226 (2010).
  Article CAS PubMed Google Scholar
• Mayer, A. M. et al. The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol. Sci. 31, 255–265 (2010).
  Article CAS PubMed Google Scholar
• Telling, J. L. et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177, 362–371 (2006).
  Article Google Scholar
• Anthes, J. C. et al. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor. Eur. J. Pharmacol. 449, 229–237 (2002).
  Article CAS PubMed Google Scholar
• Disse, B. et al. Tiotropium (Spiriva): mechanistic considerations and clinical profile in obstructive lung disease. Life Sci. 64, 457–464 (1999).
  Article CAS PubMed Google Scholar
• Vauquelin, G., Fierens, F. & Van Liefde, I. Long-lasting AT1 receptor binding and protection by candesartan: comparison to other biphenyl-tetrazole sartans. J. Hypertens. 24, S23–S30 (2006).
  Article CAS Google Scholar
• Fuchs, B. et al. Comparative pharmacodynamics and pharmacokinetics of candesartan and losartan in man. J. Pharm. Pharmacol. 52, 1075–1083 (2000).
  Article CAS PubMed Google Scholar
• Gustafsson, J. A. Raloxifene: magic bullet for heart and bone? Nature Med. 4, 152–153 (1998).
  Article CAS PubMed Google Scholar
• DiMasi, J. A. & Fadon, L. B. Competitiveness in follow-on drug R&D: a race or imitation? Nature Rev. Drug Discov. 10, 1–5 (2011).
  Article CAS Google Scholar
• Gleeson, M. P., Hersey, A., Montanari, D. & Overington, J. Probing the links between in vitro potency, ADMET and physiocochemical parameters. Nature Rev. Drug Discov. 10, 197–208 (2011).
  Article CAS Google Scholar
• Fersht, A. Enzyme Structure and Mechanism 88–109 (W. H Freeman and Company, New York,1985).
  Google Scholar
• Issa, J. P. J., Kantarjian, H. M. & Kirkpatrick, P. Azacitidine. Nature Rev. Drug Discov. 4, 275–276 (2005).
  Article CAS Google Scholar
• Martel, R. R., Klicius, J. & Galet, S. Inhibition of immune response by rapamycin, a new antifungal antibiotic. Can. J. Physiol. Pharmacol. 55, 48–51 (1977).
  Article CAS PubMed Google Scholar
• Bartizal, K. et al. In vitro antifungal activities and in vivo efficacies of 1,3-β-glucan synthesis inhibitors L671,329, L646,991, tetrahydroechinocandin B, and L687,781, a papulacandin. Antimicrob. Agents Chemother. 36, 1648–1657 (1992).
  Article CAS PubMed PubMed Central Google Scholar
• Uchikawa, O. et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J. Med. Chem. 45, 4222–4239 (2002).
  Article CAS PubMed Google Scholar
• Kenakin, T. Pharmacologic Analysis of Drug-Receptor Interaction 242–395 (Lippincott-Raven Publishers, Philadelphia, 1997).
  Google Scholar
• Burris K. D. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381–389 (2002).
  Article CAS PubMed Google Scholar
• Pulvirenti, L. & Koob, G. F. Dopamine receptor agonists, partial agonists and psychostimulant addiction. Trends Pharmacol. Sci. 15, 374–379 (1994).
  Article CAS PubMed Google Scholar
• Coe, J. E. et al. Varenicline: an α4β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. 48, 3474–3477 (2005). Describes the thinking that led to a mechanism-based search for a partial agonist of nicotinic receptors.
  Article CAS PubMed Google Scholar
• Rickter, A. M. et al. Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J. Natl Cancer Inst. 79, 1327–1332 (1987).
  Google Scholar
• Hemphill, A., Mueller, J. & Esposito, M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin. Pharmacother. 7, 953–964 (2006).
  Article CAS PubMed Google Scholar
• Rossignol, J. F. & Maisonneuve, H. Nitazoxanide in the treatment of Teania saginata and Hymenolepis nana infections. Am. J. Trop. Med. Hyg. 33, 511–512 (1984).
  Article CAS PubMed Google Scholar
• Lewis, D. A. & Lieberman, J. A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325–334 (2000).
  Article CAS PubMed Google Scholar
• Yasuda, Y. et al. 7-[3-[4-(2,3 dimethylphenyl)piperazinyl] propoxy]-2(1_H_)-quinolinone (OPC-4392), a presynaptic dopamine receptor agonist and postsynaptic D2 receptor antagonist. Life Sci. 42, 1941–1954 (1988).
  Article CAS PubMed Google Scholar
• Kikuchi, T. et al. 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1_H_)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274, 329–336 (1995).
  CAS PubMed Google Scholar
• Oshiro, Y. et al. Novel antipsychotic agents with dopamine autoreceptor agonist properties: synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1_H_)-quinolinone derivatives. J. Med. Chem. 41, 658–667 (1998).
  Article CAS PubMed Google Scholar
• Inoue, T., Domae, M., Yamada, K. & Furukawa, T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1_H_)-quinoline (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277, 137–143 (1996).
  CAS PubMed Google Scholar
• Egger, G., Liang, G., Aparicio, A. & Jones, P. A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).
  Article CAS PubMed Google Scholar
• Satistowska-Schroder, E. T., Kerridge, D. & Perry, H. Echinocandin inhibition of 1,3-β-D-glucan synthase from Candida albicans. FEBS Lett. 173, 134–138 (1984).
  Article Google Scholar
• Nishi, T. et al. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. I. Alkyl 4-(2-oxo-1,2,3,4-tetrahydro-6-quinolyloxy)butyrates and related compounds. Chem. Pharm. Bull. 31, 798–810 (1983).
  Article CAS Google Scholar
• Tally, F. P. DeBruin M. F. Development of daptomycin for Gram-positive infections. J. Antimicrob. Chemother. 46, 523–526 (2000).
  Article CAS PubMed Google Scholar
• Stock, C, C. & Francis, T. J. The inactivation of the virus of epidemic influenza by soaps. J. Exp. Med. 71, 661–681 (1940).
  Article CAS PubMed PubMed Central Google Scholar
• Snipes, W., Person, S., Keller, G., Taylor, W. & Keith, A. Inactivation of lipid-containing viruses by long-chain alcohols. Antimicrob. Agents Chemother. 11, 98–104 (1977).
  Article CAS PubMed PubMed Central Google Scholar
• Sands, J., Auperin, D. & Snipes, W. Extreme sensitivity of enveloped viruses including herpes-simplex, to long-chain unsaturated monglycerides and alcohols. Antimicrob. Agents Chemother. 15, 67–73 (1979).
  Article CAS PubMed PubMed Central Google Scholar
• Katz, D. H., Marcelletti, J. F., Khalil, M. H., Pope, L. E. & Katz, L. E. Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex. Proc. Natl Acad. Sci. USA 88, 10825–10829 (1991).
  Article CAS PubMed PubMed Central Google Scholar
• Wakeling, A. E., Dukes, M. & Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51, 3867–3873 (1991).
  CAS PubMed Google Scholar
• Stenoien, D. L. et al. FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent. Nature Cell Biol. 3, 15–23 (2001).
  Article CAS PubMed Google Scholar
• Glower, A. J., Noyer, M., Verloes, R., Gobert, J. & Wulfert, E. UCB L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. 222, 193–203 (1992).
  Article Google Scholar
• Shinabarger, D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs 8, 1195–1202 (1999).
  Article CAS PubMed Google Scholar
• Brickner, S. J. Oxazolidinone antibacterial agents. Curr. Pharm. Des. 2, 175–194 (1996).
  CAS Google Scholar
• Cuppoletti J. et al. Recombinant and native intestinal cell ClC-2 Cl− channels are activated by RU-0211. Gastroenterology 122, A538 (2002).
  Google Scholar
• Cuppoletti, J. et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am. J. Physiol. 287, C1173–C1183 (2004).
  Article CAS Google Scholar
• Peña-Münzenmayer, G. et al. Basolateral localization of native ClC-2 chloride channels in absorptive intestinal epithelial cells and basolateral sorting encoded by a CBS-2 domain di-leucine motif. J. Cell Sci. 118, 4243–4252 (2005).
  Article CAS PubMed Google Scholar
• Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well-tolerated _N_-methyl-D-aspartate (NMDA) receptor antagonist — a review of the preclinical data. Neuropharmacology 38, 735–767 (1999).
  Article CAS PubMed Google Scholar
• Gerzon, K. et al. The adamantyl group in medicinal agents. I. Hypoglycemic _N_-arylsulfonyl-_N_′-adamantylureas. J. Med. Chem. 6, 760–763 (1963).
  Article CAS PubMed Google Scholar
• Bormann, J. Memantine is a potent blocker of _N_-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166, 591–592 (1989).
  Article CAS PubMed Google Scholar
• Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. _N_-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362–8365 (1994).
  CAS PubMed Google Scholar
• Pastores, G. M. & Barnett, N. L. Substrate reduction therapy: miglustat as a remedy for symptomatic patients with Gaucher disease type 1. Expert Opin. Investig. Drugs. 12, 273–281 (2003).
  Article CAS PubMed Google Scholar
• Hu, S. et al. Pancreatic β-cell KATP channel activity and membrane-binding studies with nateglinide: a comarison with sulfonylureas and repaglinide. J. Pharmacol. Ther. 293, 444–452 (2000).
  CAS Google Scholar
• Shinkai, H. et al. _N_-acylphenylanalines and related compounds. A new class of oral hypoglycemic agents. J. Med. Chem. 31, 2092–2097 (1988).
  Article CAS PubMed Google Scholar
• Shinkai, H. et al. _N_-acylphenylanalines and related compounds. A new class of oral hypoglycemic agents. J. Med. Chem. 32, 1436–1441 (1989).
  Article CAS PubMed Google Scholar
• Parker, W. B. et al. Purine nucleoside analogues in development for the treatment of cancer. Curr. Opin. Investig. Drugs 5, 592–596 (2004).
  CAS PubMed Google Scholar
• Rodriguez, C. O. et al. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 102, 1842–1848 (2003).
  Article CAS PubMed Google Scholar
• Krenitsky, T. A. et al. An enzymatic synthesis of purine-D-arabinonucleosides. Carbohydr. Res. 97, 139–146 (1981).
  Article CAS Google Scholar
• Lambe, C. U. et al. 2-amino-6-methoxypurine arabinoside: an agent for T-cell malignancies. Cancer Res. 55, 3352–3356 (1995).
  CAS PubMed Google Scholar
• Gandhi, V., Keating, M. J., Bate, G. & Kirkpatrick, P. Nelarabine. Nature Rev. Drug Discov. 5, 17–18 (2006).
  Article CAS Google Scholar
• Lock, E. A. et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC), its toxicology and development as a drug. J. Inherit. Metab. Dis. 21, 498–506 (1998).
  Article CAS PubMed Google Scholar
• Kavana, M. & Moran, G. R. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-Nitro-4-(trifluoromethyl)benzoly]-1,3-cyclohexanedione. Biochemistry 42, 10238–10245 (2003).
  Article CAS PubMed Google Scholar
• Brownlee, J. M., Johnson-Winters, K., Harrison, D. H. T. & Moran, G. R. Structure of the ferrous form of 4-(hydroxyphenyl)pyruvate dehydrogenase from Streptomyces avermitilis in complex with the therapeutic herbicide, NTBC. Biochemistry 43, 6370–6377 (2004).
  Article CAS PubMed Google Scholar
• Yanagihara, Y., Kasai, H., Kawashima, T. & Shida, T. Immunopharmacological studies on TBX, a new antiallergic drug (1). Inhibitory effects on passive cutaneous anaphylaxis in rats and guinea pigs. Jpn. J. Pharmacol. 48, 91–101 (1988).
  Article CAS PubMed Google Scholar
• Gaffney, S. M. Ranolazine, a novel agent for chronic stable angina. Pharmacotherapy 26, 135–142 (2006).
  Article CAS PubMed Google Scholar
• Chaitman, B. R. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375–1382 (2004).
  Article CAS PubMed Google Scholar
• Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309–316 (2004).
  Article CAS PubMed Google Scholar
• Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904–910 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Hunt, E. Pleuromutilin antibiotics. Drugs Future 25, 1163–1168 (2000).
  Article CAS Google Scholar
• Jain, K. K. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin. Investig. Drugs 9, 829–840 (2000).
  Article CAS PubMed Google Scholar
• Rogawski, M. A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69, 273–294 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Meltzer, S. M., Monk, B. J. & Tewari, K. S. Green tea catechins for treatment of external genital warts. Am. J. Obstet. Gynecol. 200, 233.e1–233.e7 (2009).
  Article CAS Google Scholar
• Vezina, C., Kudelski, A. & Shegal, S. N. Rapamycin. (AY-22,989), a new antifungal antibiotic. I. Taxomony of the producing streptomycete and isolation of the active principle. J. Antibiot. 10, 721–726 (1975).
  Article Google Scholar
• Richon, V. M. et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc. Natl Acad. Sci. USA 93, 5705–5708 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Marks, P. A. & Breslow, R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature Biotech. 25, 84–90 (2007).
  Article CAS Google Scholar
• Masuda Y. et al. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: pharmacological profile. Arzneimittelforschung 30, 477–483 (1980).
  CAS PubMed Google Scholar
• Maibaum, J. et al. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent non-peptide human renin inhibitor active after once daily dosing in marmosets. J. Med. Chem. 50, 4832–4844 (2007).
  Article CAS PubMed Google Scholar
• Goldberg, A. in Cancer Drug Discovery and Development: Proteasome Inhibitors in Cancer Therapy (ed. Adams, J.) 17–38 (Humana, Totowa, 2004).
  Book Google Scholar
• Stein, R. L., Ma, Y. T. & Brand, S. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein. US Patent 5,693,617 (1995).
• Decaux, G., Soupart, A. & Vassart, G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371, 1624–1632 (2008).
  Article CAS PubMed Google Scholar
• Flexner, C. HIV drug development: the next 25 years. Nature Rev. Drug Discov. 6, 959–966 (2007).
  Article CAS Google Scholar
• Tsibris, A. M. & Kuritzkes, D. R. Chemokine antagonists as therapeutics: focus on HIV-1. Annu. Rev. Med. 58, 445–459 (2007).
  Article CAS PubMed Google Scholar
• Dorr, P. et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Watson, C., Jenkinson, S., Kazmierski, W. & Kenakin, T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol. Pharmacol. 67, 1268–1282 (2005).
  Article CAS PubMed Google Scholar
• Pincus, G. (ed.) The Control of Fertility. 128–138 (Academic Press, New York, 1965).
  Google Scholar
• Belanger, A., Philibert, D. & Teutsch, G. Regio and stereospecific synthesis of 11β-substituted 19-norsteroids. Steroids 37, 361–382 (1981).
  Article CAS PubMed Google Scholar
• Mahajan, D. K. & London, S. N. Mifepristone (RU486): a review. Fertil. Steril. 68, 967–976 (1997).
  Article CAS PubMed Google Scholar
• Raaijmakers, H. C., Versteegh, J. E. & Uitdehaag, J. C. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J. Biol. Chem. 284, 19572–19579 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Hadvary, P., Lengsfeld, H. & Wolfer, H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 256, 357–361 (1988).
  Article CAS PubMed PubMed Central Google Scholar
• Hazuda, D. J. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646–650 (2000).
  Article CAS PubMed Google Scholar
• Summa, V. et al. Discovery of raltegravir. A potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J. Med. Chem. 51, 5843–5855 (2008).
  Article CAS PubMed Google Scholar
• Buysse, D., Bate, G. & Kirkpatrick, P. Ramelteon. Nature Rev. Drug Discov. 4, 881–882 (2005).
  Article CAS Google Scholar
• Drucker, D. J. The biology of incretin hormones. Cell. Metab. 3, 153–165 (2006).
  Article CAS PubMed Google Scholar
• Cohen, H. T. & McGovern, F. J. Renal-cell carcinoma. N. Engl. J. Med. 353, 2477–2490 (2005).
  Article CAS PubMed Google Scholar
• Atkins, M. B. et al. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin. Cancer Res. 9, 6277S–6281S (2004).
  Article Google Scholar
• Bergers, G. et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287–1295 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Mendel, D. B. et al. In vivo anti-tumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
  CAS PubMed Google Scholar
• De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13–25 (2002).
  Article CAS Google Scholar
• Boismare, F. et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol. Biochem. Behav. 21, 787–789 (1984).
  Article CAS PubMed Google Scholar
• Kennedy, J. C., Pottier, R. H. & Pross, D. C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B 6, 143–148 (1990).
  Article CAS PubMed Google Scholar
• Sima, A. A. F., Kennedy, J. C., Blakeslee, D. & Robertson, D. M. Experimental porphyric neuropathy: a preliminary report. Can. J. Neurol. Sci. 8 105–114 (1981).
  Article CAS PubMed Google Scholar
• Choay, J. et al. Structure–activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. 116, 492–499 (1983).
  Article CAS PubMed Google Scholar
• Hirsh, J. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119, 64S–94S (2001).
  Article CAS PubMed Google Scholar
• Walenga, J. M. et al. Development of a synthetic heparin pentasaccharide: fondaparinux. Turk. J. Haematol. 19, 137–150 (2002).
  CAS PubMed Google Scholar
• Blau, N. & Erlandsen, H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 82, 101–111 (2004).
  Article CAS PubMed Google Scholar
• Niederwieser, A. & Curtius, H. C. in Inherited Diseases of Amino Acid Metabolism (eds Bickel, H. & Wachtel, U.) 104–121 (Georg Thieme, Stuttgart, 1985).
  Google Scholar
• Kure, S. et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J. Pediatr. 135, 375–378 (1999).
  Article CAS PubMed Google Scholar
• Muntau, A. C. et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N. Engl. J. Med. 347, 2122–2132 (2002).
  Article CAS PubMed Google Scholar
• Mellish, K. J. & Brown, S. B. Verteporfin: a milestone in ophthalmology and photodynamic therapy. Expert Opin. Pharmacother. 2, 351–361 (2001).
  Article CAS PubMed Google Scholar